Citius Pharmaceuticals, Inc. (CTXR) stock
Close on Nov 12, 2026Market cap $14.62MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $14.62M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.22
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- EPS, diluted
- -$2.13
- Book value per share
- $2.55
- Diluted shares
- 26M
Trading
- Next earnings
- Feb 12, 2027 (estimated, before the open)
- Previous close
- $0.48
- Open
- $0.47
- Day's range
- $0.46 – $0.57
- Volume
- 650,822
- Average volume (20 days)
- 310,464
- Beta (5 years)
- 1.53
- 52-week range
- $0.37 – $1.54
- RSI (14 days)
- 44.5
- Volatility (1 year)
- 108.9%
- Relative volume
- 0.39×
- WACC
- 4.2%
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CTXR | S&P 500 | Difference | CTXR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +8.0% | -2.7% | +10.7 pts | ||
| 3 months | -30.4% | -1.7% | −28.7 pts | ||
| Year to date | -31.5% | +11.9% | −43.4 pts | ||
| 1 year | -51.8% | +12.0% | −63.8 pts | ||
| 3 years | -97.2% | +78.2% | −175.4 pts | -69.8% | +21.2% |
| 5 years | -98.8% | +73.2% | −172.1 pts | -59.0% | +11.6% |
| 10 years | -99.7% | +309.6% | −409.3 pts | -43.8% | +15.1% |
Twelve years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Citius Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Results
- News
- News
- Results
About Citius Pharmaceuticals
Pharmaceutical Preparations
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of critical care therapeutic products. Its operations center on oncology, anti-infectives used in adjunct cancer care, and specialized prescription therapies. The company's portfolio features an approved oncology treatment, denileukin diftitox (marketed as LYMPHIR), for patients with persistent or recurrent cutaneous T-cell lymphoma. Additionally, its late-stage development pipeline includes Mino-Lok, an antibiotic lock solution engineered to salvage infected central venous catheters, Halo-Lido, a topical anti-inflammatory and anesthetic formulation for hemorrhoids, and a mesenchymal stem cell therapy for acute respiratory distress syndrome.
Company profile, executives and historyCitius Pharmaceuticals stock: common questions
What is Citius Pharmaceuticals's stock price?
CTXR closed at $0.53 on Nov 12, 2026, up 10.78% on the day. Over the past 52 weeks it traded between $0.37 and $1.54.
What is Citius Pharmaceuticals's market cap?
Citius Pharmaceuticals was worth $14.62M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is CTXR's P/E ratio?
Citius Pharmaceuticals lost money over the twelve months to Jun 30, 2026 (diluted EPS -$2.13), so it has no meaningful P/E ratio.
Does Citius Pharmaceuticals pay a dividend?
No. Citius Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Citius Pharmaceuticals report earnings next?
Citius Pharmaceuticals is expected to report Q1 FY2027 results on Feb 12, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CTXR stock performed over the past year?
Including dividends, CTXR returned -51.8% over the past year, against +12.0% for the S&P 500.
How many CTXR shares are sold short?
6M shares were sold short at the latest FINRA report, 21.66% of the float, or 17.8 days of average trading volume.
Who are Citius Pharmaceuticals's competitors?
Companies most similar to Citius Pharmaceuticals by business, industry and size include CTOR, SNGX, CRMD, TLPH, SNDX.
See a number that looks wrong?